Sökning: "IFNγ"
Visar resultat 1 - 5 av 45 avhandlingar innehållade ordet IFNγ.
1. Synergistic effects of mesenchymal stromal cells and immunotherapy in experimental brain tumors
Sammanfattning : Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain tumor. In spite of surgical resection, combined radiation therapy and chemotherapy, the mean survival is less than 15 months following diagnosis. LÄS MER
2. Functional genetic studies of Psoriasin: a potential biomarker for breast cancer with a poor prognosis
Sammanfattning : Breast cancer is the most common malignancy in women. There is a high degree of heterogeneity in breast tumours and they can be divided into subtypes that have different expression pattern and clinical outcome. Ductal Carcinoma in situ (DCIS) is regarded as a precursor of invasive ductal breast cancer. LÄS MER
3. Towards Immunotherapy of Midgut Carcinoid Tumors
Sammanfattning : Classical midgut carcinoids belong to neuroendocrine tumors of the gastroenteropancreatic tract (GEP-NETs) and are associated with serotonin overproduction. The term midgut is derived from the tumors’ embryological site of origin: enterochromaffin cells in the lower jejunum, ileum, caecum and the ascending colon. LÄS MER
4. Combined chemotherapy and immunotherapy against experimental malignant brain tumors
Sammanfattning : Glioblastoma multiforme (GBM) is the most common and aggressive primary malignant brain tumor in adults. Despite standard treatment including surgery, radiotherapy and temozolomide (TMZ)-based chemotherapy, the prognosis for GBM patients is dismal, and there is a need for novel treatments. LÄS MER
5. Immunotherapy against malignant brain tumors - of mice and men
Sammanfattning : Glioblastoma Multiforme (GBM) is the most abundant and most aggressive primary brain tumor in adults. Due to the infiltrative growth of the tumor, surgery will never be radical. Radiation and chemotherapy only marginally improve the poor prognosis due to the ability of the GBM to develop resistance towards these treatments. LÄS MER